Loading...
Loading...
PSNL| Name | Value |
|---|---|
| Revenues | 22.6M |
| Cost of Revenue | 14.5M |
| Gross Profit | 8.0M |
| Operating Expense | 24.9M |
| Operating I/L | -16.9M |
| Other Income/Expense | 4.1M |
| Interest Income | 1.1M |
| Pretax | -12.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.8M |
Personalis, Inc. is a global cancer genomics company that offers sequencing and data analysis services to support cancer therapy development and genetic research programs. The company's NeXT Platform provides comprehensive data analysis for tumor and immune microenvironment from limited tissue or plasma samples, catering to personalized tumor tracking and genomic cancer profiling. Additionally, its ACE platform is utilized for clinical and therapeutic applications, including neoantigen prediction and drug target selection. Personalis serves biopharmaceutical customers, universities, non-profits, and government entities, generating revenue through its sequencing and data analysis services, as well as through partnerships with leading healthcare and biotech organizations.
